Investor Overview

Corporate Profile
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Our first investigational product candidate, NeoCart®, leverages our platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee. For more information on Histogenics, please visit the company website at www.histogenics.com.
Stock Quote
HSGX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$2.25
Change (%) Stock is Up 0.07 (3.21%)
Volume70,796
Data as of 10/20/17 3:59 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent NewsMore >>
DateTitle 
10/12/17Histogenics Corporation Promotes Stephen Kennedy to Executive Vice President & Chief Operating Officer
WALTHAM, Mass., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leading cell therapy company focused on developing and commercializing products in the musculoskeletal space, today announced the promotion of Stephen Kennedy from Chief Technology Officer to Executive Vice President & Chief Operating Officer, effective October 12, 2017.  Mr. Kennedy brings more than 30 years of executive product development, manufacturing, technology assessment and com... 
Printer Friendly Version
10/02/17Histogenics Announces Publication of Additional Biomechanical Data From Human Engineered Cartilage Testing
– Data Demonstrate the Importance of Generating Extracellular Matrix During Ex-Vivo Manufacturing of Cartilage Cell Therapy – – Ex-vivo Production of Extracellular Matrix is Critical to Biomechanical Competence and May Enable Earlier Return to Function After Treatment – – Presence of Extracellular Matrix at Time of Implantation Improves Biomechanical Competence of Cartilage Cell Therapy Compared to Therapies with Only Cells and Scaffold – WALTHAM, Mass., Oct. 02, 2017 (GLOBE NEWSWIRE) --... 
Printer Friendly Version
09/26/17Histogenics Corporation to Present at the 2017 Cell & Gene Meeting on the Mesa
WALTHAM, Mass., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leading cell therapy company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will be participating in a panel discussion on tissue engineering on Wednesday, October 4, 2017 at 10:45 am PT and presenting a corporate overview during the meeting’s Partnering Forum on Wedne... 
Printer Friendly Version
08/24/17Histogenics Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be presenting at three upcoming conferences in September 2017.  Baird 2017 Global Healthcare Conference – New York, NY (September 6-7, 2017) Jonathan Lieber, Chief Financial Officer of Histogenics, will be presenting a corporat... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Contact Information

Histogenics Corporation
Phone: 781.547.7900
E-mail: InvestorRelations@histogenics.com

Featured Documents
View the Company Profile
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Histogenics Corp posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.